NCT02343549 2022-11-03A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)Wake Forest University Health SciencesPhase 2 Terminated13 enrolled 23 charts